SEC Form 4 · accession 0001209191-18-038596
Verrica Pharmaceuticals Inc. · VRCA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Glenn A Oclassen
Director
Period of report
Jun 19, 2018
Accepted (ET)
Jun 19, 2018 · 4:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660334
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 19, 2018 | C | 200,734 | — | A | 290,421 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Convertible Preferred StockF2,F1 | — | Jun 19, 2018 | C | 200,734 | D | — | — | Common Stock | 200,734 | 0 | I |
Explanation of responses
- F1Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering.
- F2The shares are held directly by The Glenn A. Oclassen 2016 Trust dated November 30, 2016 (the "Trust"). The Reporting Person serves as trustee of the Trust.